Artificial Intelligence
GCAC Closes Largest Revenue Deal for its Efixii ‘Seed to Seed’ Platform with Malta Based Medical Cannabis Cultivator
VANCOUVER, British Columbia, April 13, 2021 (GLOBE NEWSWIRE) — Global Cannabis Applications Corp. (“GCAC” or the “Company”) (CSE: APP, FSE: 2FA, OTCQB: FUAPF), a leading medical cannabis chain-of-custody compliance, efficacy and data platform, today announced a definitive three-year software licensing agreement with Herb Industries Ltd. (“Herb”), a Malta based medical cannabis cultivator. Grams cultivated are forecast as 44M in 2022 and 66M in 2023.
GCAC is licensing its Citizen Green Efixii platform as part of Herb’s ‘technology farm’ for use in its cannabis compliance and consumer transparency. Herb’s advanced-growth-method handles all production lifecycles from genetics, cannabis nursery, onsite ISO laboratory and extraction. Licensed by the Maltese government, Herb’s 12,000 SQM facility’s manufacturing lines will export to other EU members’ markets for pharmaceutical, solids, semi solids, liquids, flowers, cosmetics and edibles.
GCAC’s Software-as-a-Service (“SaaS”) license model meets the needs of cultivators as they scale. Cannabis lifecycle steps are represented by GCAC’s Efixii QR-code which can be scanned by customs officials, regulators, medical professionals and consumers alike to ensure that products are what they claim to be. GCAC charges a one-time configuration fee of $12,500 (USD), $50 per registered employee per month for KYC/AML, an export fee of $75 per cannabis batch and a consumer Efficacy-QR-code fee of $75 per retail product; in total, these fees generate CDN$.20/gram with a further potential yield of CDN$.18/gram in future data sales.
“44M grams in 2022 and 66M grams every year thereafter is an absolutely massive revenue opportunity for us on a per gram basis” states GCAC’s CEO Brad Moore. “And, just as important is knowing that tens of thousands of EU consumers trust Efixii’s QR-codes to give them, and their families, comfort knowing what they are ingesting is the safest and best product for them, thereby cementing our efficacy commitment of better outcomes for all medical cannabis patients.”
The European cannabis market is the largest in the world, with a forecast CAGR of 67.4% set to value the market at €3.2 billion by 2025 [1]. The growth of the EU market since 2019 is attributed to consumer demand for CBD and the upgrading of regulations for medical cannabis. Key to meeting those regulations and building consumer confidence will be Herb’s use of the Efixii compliance platform. Efixii enables growers’ staff to record all events for cannabis cultivations, including mother plant, laboratory tests, shipment, processing and customs.
All of Efixii’s cannabis data is the intellectual property (“IP”) of GCAC. This IP creates an inherent difficulty in replicating or competing with GCAC’s medical cannabis datasets. GCAC defined their protocols in a provisional U.S. patent application, ‘System of Process and Tracking Cannabis Products and Associated Method Using Blockchain’ filed with the USPTO on Dec. 17, 2020.
About Global Cannabis Applications Corp.
Global Cannabis Applications Corp. is a global leader in designing, developing, marketing and acquiring innovative data technologies for the medical cannabis industry. The Citizen Green platform is the world’s first end-to-end – from patient to regulator – medical cannabis data solution. It uses six core technologies: mobile applications, artificial intelligence, regtech, smart databases, blockchain and GCAC smart rewards to qualify candidates for clinical studies. These technologies facilitate the proliferation of digital conversations by like-minded people in the medical cannabis community. Driven by digital and cannabis industry experts, GCAC is focused on viral global expansion by providing the best digital experience in the cannabis market.
For more Company information, please visit www.cannappscorp.com, or review its profiles on www.sedar.com and on the Canadian Securities Exchange’s website (www.thecse.com).
| To schedule an interview, please contact: | For more information, please contact: |
| Bradley Moore | Corporate Communications |
| Chief Executive Officer | Telephone: +1 (800) 409-5679 |
| Email: [email protected] | Email: [email protected] |
Forward-Looking Information
This news release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of GCAC. Forward-looking information is based on certain key expectations and assumptions made by the management of GCAC. Although management of the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because GCAC can give no assurance that they will prove to be correct. Forward-looking statements contained in this news release are made as of the date of this news release. GCAC disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy and accuracy of this information.
Artificial Intelligence
Praesidiad takes High Court action against competitor and ex-employees for alleged wrongdoing
LONDON, May 7, 2024 /PRNewswire/ — Through its subsidiary, Hesco Bastion Limited (Hesco), legal action has been commenced in the High Court in London against Dirickx Systems Limited (Dirickx) and a number of ex-employees of Hesco. The claim involves allegations of misuse of confidential information, breach of employee’s duties of good faith, infringement of patent and copyright as well as misrepresentations to customers.
The allegations of wrongdoing include the removal by the ex-employees, either alone or together, of commercially sensitive information, confidential to Hesco.
Hesco is seeking orders from High Court for appropriate injunctions to restrain further infringing activity, an enquiry into damages or alternatively an account of Dirickx’s profits as well as payment of its legal costs. A High Court trial in London is expected within 12-18 months.
Dino Koutrouki, CEO, said “Whilst Praesidiad as a business welcomes legitimate competition, it is not prepared to allow the actions of former employees, placed in a position of trust and duty of good faith, to unlawfully take advantage of the foundations of our business in order compete with us.
Hesco has a proud history as a leading innovator. For over 30 years customers have depended on us for original, high quality life safety products conceived, created and developed by us and tested independently to the highest standards. We have a duty to defend our innovation and our brand through this High Court action. Hesco intends to pursue its claims to the fullest degree, and we confidently expect the litigation process will reveal the full extent of wrongdoing of which the above is only a snapshot.”
Full details of our claim can be viewed on our website and here: Particulars_of_Infringement
Particulars_of_Claim
About Praesidiad
PRÆSIDIAD (www.praesidiad.com) owned brands Betafence and Hesco are market leaders in integrated perimeter and physical security solutions. Global Manufacturers of fencing products, defensive barriers, body armor and industrial mesh; manufacturing and supplying protection around the world.
About HESCO
Hesco (www.hesco.com) is a world leader and innovator in defence, perimeter protection and security systems, including defensive barriers, flood barriers, rapid deployment systems, safe haven bunkers and ballistic resistant body armor.
Hesco is synonymous with force protection and is recognised across its industry for its commitment to saving lives, property and the environment, whenever and wherever it is needed.
Photo – https://mma.prnewswire.com/media/2403823/HESCO.jpg
View original content:https://www.prnewswire.co.uk/news-releases/praesidiad-takes-high-court-action-against-competitor-and-ex-employees-for-alleged-wrongdoing-302134886.html
AMSTERDAM, May 7, 2024 /PRNewswire/ — In a move that underscores its innovation in smart cleaning technology, Pudu Robotics (“PUDU”), the global leader in service robotics, is set to captivate the cleaning industry with its first appearance at the prestigious Interclean Amsterdam 2024, the largest professional cleaning trade show in the world and unsurpassed in its role as an international business networking platform for the cleaning and hygiene industry.
From May 14-17, PUDU’s booth in Hall 5 05.317 at RAI Amsterdam will serve as a beacon for innovation, inviting industry professionals to explore the new cleaning frontier, where they will have the exclusive opportunity to witness cutting-edge advancements in cleaning technology.
The spotlight of this year’s showcase is undoubtedly on the official debut of the highly anticipated and newly upgraded PUDU SH1, a smart upright scrubber dryer that is set to redefine cleaning efficiency and effectiveness. Scheduled for May 14th between 14:00-15:00, an unveiling ceremony will introduce attendees to this next-generation cleaner. This event will include insightful presentations from product experts detailing key upgrades of PUDU SH1 and an overview of new solutions provided by its counterpart, PUDU CC1.
In addition to product introductions, visitors are encouraged to engage with live demonstrations taking place at the Robot Arena throughout the exhibition days.
PUDU’s Daily Demonstration Schedule at the Robot Arena
– Tuesday, May 14: Sessions at 10:45, 12:30, 14:15, and 16:00- Wednesday, May 15: Sessions at 11:15, 13:00, 14:45, and 16:30- Thursday, May 16: Sessions at 10:15, 12:00, 13:45, 15:30 and 17:15- Friday, May 17: Session at 11:30
These sessions offer a hands-on experience with PUDU CC1 while facilitating direct interaction with specialists who can provide deeper insights into their operational capabilities and benefits.
PUDU is enthusiastic about engaging with fellow innovators and stakeholders who are keen on developing future clean environments through intelligent technology. By showcasing its technological prowess and commitment to advancing smart cleaning solutions, PUDU aims to showcase new products, foster industry connections and seek potential partnerships at Interclean Amsterdam 2024.
To learn more about the latest information on cleaning products and to gain an immersive experience, visitors can register through the following link to obtain FREE tickets from PUDU:
https://register.visitcloud.com/survey/2hdir9zqg5391?actioncode=NTWO001675WTZ&partner-contact=03bjh516im8tu
About Pudu Robotics
Pudu Robotics, a global leader in the service robotics sector, is dedicated to enhancing human productivity and living standards through innovative robot technology. With a focus on R&D, manufacturing, and sales of service robots, Pudu Robotics holds nearly a thousand authorized patents worldwide, encompassing a wide range of core technologies. The company’s robots have been widely adopted in various industries, including dining, retail, hospitality, healthcare, entertainment, education, and manufacturing. To date, Pudu Robotics has successfully shipped over 70,000 units to a variety of markets, with a presence in more than 60 countries and regions worldwide.
For more information on business developments and updates, follow PUDU on Facebook, YouTube, LinkedIn, Twitter, and Instagram.
Photo – https://mma.prnewswire.com/media/2406274/Pudu_Robotics_takes_part_Interclean_Amsterdam_2024.jpgLogo – https://mma.prnewswire.com/media/2193118/Pudu_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/pudu-robotics-debuts-advanced-smart-cleaning-tech-at-interclean-amsterdam-302137623.html
Artificial Intelligence
Clarivate Introduces Epidemiology Intelligence™ for Precision Patient Population Analysis
Empowering biopharma with unified epidemiology, incidence and prevalence data alongside claims-based population insights, for precise market sizing and patient population analysis
LONDON, May 7, 2024 /PRNewswire/ — Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced the launch of Epidemiology Intelligence™. The new solution combines rich insights from epidemiology, incidence and prevalence database solutions. It includes U.S. claims-based population insights to empower biopharma companies to accurately gauge market size and target patient demographics with ease.
In today’s rapidly evolving market landscape, precise forecasting is essential for biopharmaceutical companies. Yet, traditional research methods often come with limitations that can lead to inaccurate estimations and costly consequences. Epidemiology Intelligence empowers users with unique insights to address critical questions about the drug-treatable population. The solution facilitates precise assessments, identification of niche populations and accurate predictions based on population insights.
Ravindra Sharma, VP Product Management, Clarivate, said: “The launch of Epidemiology Intelligence marks a significant milestone for Clarivate in our ongoing commitment to deliver comprehensive and actionable solutions to life sciences and healthcare companies. Clients can now access comprehensive coverage of disease epidemiology paired with expert analysis, seamlessly integrated into a unified platform. The new solution enables them to deliver safe, effective and commercially successful treatments to patients faster.”
Epidemiology Intelligence accelerates data-driven decision-making across the drug development lifecycle. Clients can benchmark market forecasts, validate investments, pinpoint growth opportunities and utilize the solution to strategically position their products for success.
To learn more about Epidemiology Intelligence, visit here.
About Epidemiology Intelligence
Epidemiology Intelligence is a new, unified Clarivate patient population offering that brings together our legacy Epidemiology and Incidence and Prevalence Database solutions, as well as claims-based population insights, on a single platform. This transformative solution offers user-friendly visualizations, easy data exports and a unique breadth and depth of patient population insights. Conduct thorough market assessment with comprehensive coverage across 1200+ diseases and procedures. Dive deep into expert disease-specific epidemiology analysis and 10 and 20-year forecasts across 220 indications and over 5000 patient populations. Leverage expanded patient segmentation and location granularity with insights sourced from Clarivate U.S. Real-World Data.
About ClarivateClarivate™ is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit www.clarivate.com
Media Contact:Catherine DanielDirector External Communications, Life Sciences & [email protected]
Logo – https://mma.prnewswire.com/media/1159266/Clarivate_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/clarivate-introduces-epidemiology-intelligence-for-precision-patient-population-analysis-302136896.html
-
Artificial Intelligence4 days agoCleverTap launches Clever.AI, the AI-Driven Edge for Customer Engagement & Retention
-
Uncategorized4 days agoImproving the Developer Journey in Crafting Artificial Intelligence Applications
-
Artificial Intelligence6 days agoAppdome Unveils World’s First Agentless Mobile EDR & MTD
-
Uncategorized4 days ago
Unveiling the Complex Psychological Implications of Artificial Intelligence
-
Artificial Intelligence4 days ago5G Enterprise Market Projected to Reach $115.81 billion by 2030 – Exclusive Report by 360iResearch
-
Artificial Intelligence4 days agoBitrue expands Bitcoin Runes Offerings with GPTV Listing and Staking Options
-
Artificial Intelligence4 days agoAppian Named a Leader in the 2024 Gartner® Magic Quadrant™ for Process Mining Platforms Report
-
Uncategorized4 days ago
AI Expert Urges New Mexico Lawmakers to Strengthen Regulation Efforts
